Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $60.5 million.

  • Karyopharm Therapeutics' Cash & Equivalents fell 3841.18% to $60.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $60.5 million, marking a year-over-year decrease of 3841.18%. This contributed to the annual value of $60.5 million for FY2025, which is 3841.18% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Cash & Equivalents of $60.5 million as of Q4 2025, which was down 3841.18% from $37.7 million recorded in Q3 2025.
  • Karyopharm Therapeutics' 5-year Cash & Equivalents high stood at $190.5 million for Q4 2021, and its period low was $30.6 million during Q1 2024.
  • Its 5-year average for Cash & Equivalents is $86.9 million, with a median of $81.6 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 12167.53% in 2021, then plummeted by 6356.5% in 2024.
  • Karyopharm Therapeutics' Cash & Equivalents (Quarter) stood at $190.5 million in 2021, then decreased by 29.02% to $135.2 million in 2022, then crashed by 61.36% to $52.2 million in 2023, then surged by 88.2% to $98.3 million in 2024, then plummeted by 38.41% to $60.5 million in 2025.
  • Its Cash & Equivalents was $60.5 million in Q4 2025, compared to $37.7 million in Q3 2025 and $38.7 million in Q2 2025.